The complications of hypertension in pregnancy

Minerva Medica

Volumn 96, Issue 4, 2005, Pages 287-302

  Von Dadelszen, P ^a,b,c   Menzies, J ^a,b   Magee, L A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NONE   (Canada)

Author keywords

Hypertension; Pre eclampsia; Pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; GLUCONATE CALCIUM; HYDRALAZINE; ISRADIPINE; LABETALOL; LIPID; MAGNESIUM SULFATE; NIFEDIPINE;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS; DELIVERY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; EUROPE; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LIPID BLOOD LEVEL; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; MATERNAL MORTALITY; META ANALYSIS; MICROALBUMINURIA; MUSCLE WEAKNESS; NORTH AMERICA; OLIGURIA; ONSET AGE; PARALYSIS; PERINATAL MORBIDITY; PERINATAL MORTALITY; PREECLAMPSIA; PREGNANCY COMPLICATION; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SEIZURE; SOLUTIO PLACENTAE; SYSTEMATIC REVIEW; TOXICITY; TREATMENT OUTCOME;

ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME;

EID: 27844585836     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Pregnancy-related mortality surveillance - United States, 1987-1990. MMWR 1997;46 SS-4):17-36.
2. Biaggi A, Paradisi G, Ferrazzani S, De Carolis S, Lucchese A, Caruso A. Maternal mortality in Italy, 1980-1996. Eur J Obstet Gynecol Reprod Biol 2004;114:144-9.
3. Health Canada. Special report on maternal mortality and severe morbidity in Canada - enhanced surveillance: the path to prevention. Ottawa: Minister of Public Works and Government; 2004.
4. von Dadelszen P, Magee LA, Marshall JC, Rotstein OD. The maternal syndrome of preeclampsia: a forme fruste of the systemic inflammatory response syndrome. Sepsis 2000;4:43-7.
5. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregn 2003;22:143-8.
6. Belfort MA. Scoring systems for eclampsia. Crit Care Med 2000;28:272-3.
7. Bhagwanjee S, Paruk F, Moodley J, Muckart DJ. Intensive care unit morbidity and mortality from eclampsia: an evaluation of the Acute Physiology and Chronic Health Evaluation II score and the Glasgow Coma Scale score. Crit Care Med 2000;28:120-4.
8. CDC US.. Preeclampsia. http://www cdc gov nchs/2002
9. Preeclampsia Foundation. Preeclampsia. http://www preeclampsia org 2002
10. Confidential Enquiry into Maternal and Child Health. Why mothers die 2000 - 2003; the sixth report of the confidential enquiries into maternal deaths in the United Kingdom. London: RCOG Press; 2004.
11. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22.
12. Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust NZ J Obstet Gynaecol 2000;40:139-55.
13. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997;157:715-25.
14. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447-51.
15. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049-59.
16. von Dadelszen P, Magee LA, Lee SK, Stewart SD, Simone C, Koren G et al. Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity? Crit Care Med 2002;30:1883-92.
17. Bulfin MJ, Lawler PE. Problems associated with toxemia in twin pregnancies. Am J Obstet Gynecol 1957;73:37-42.
18. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-4.
19. Fuchisawa A, van Eeden S, Magee LA, Whalen B, Leung PCK, Russell JA et al. Neutrophil apoptosis in preeclampsia, do steroids confound the relationship? J Obstet Gynaecol Res 2004;30:342-8.
20. Redman CWG, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180 2 Pt 1.:499-506.
21. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995;102:20-5.
22. von Dadelszen P, Watson RWG, Noorwali F, Marshall JC, Parodo J, Farine D et al. Maternal neutrophil apoptosis in normal pregnancy, preeclampsia, and normotensive intrauterine growth restriction. Am J Obstet Gynecol 1999;181:408-14.
23. von Dadelszen P, Wilkins T, Redman CWG. Maternal peripheral blood leukocytes in normal and preeclamptic pregnancies. Br J Obstet Gynaecol 1999;106:576-81.
24. von Dadelszen P. Activation of maternal peripheral blood leukocytes in pre-eclampsia. Oriel College: University of Oxford; 2000.
25. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ 1999;318:1332-6.
26. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy ISSHP.. Hypertens Pregnancy 2001;20:IX-XIV.
27. Douglas KA, Redman CWG. Eclampsia in the United Kingdom. BMJ 1994;309:1395-400.
28. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001;97:533-8.
29. Opsjon SL, Austgulen R, Waage A. Interleukin-1, interleukin-6 and tumor necrosis factor at delivery in preeclamptic disorders. Acta Obstet Gynecol Scand 1995;74:19-26.
30. Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986;155:1011-6.
31. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001;323:1213-7.
32. Smith GCS, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001;357:2002-6.
33. Xiong X, Demianczuk NN, Buekens P, Saunders LD. Association of preeclampsia with high birth weight for age. Am J Obstet Gynecol 2000;183:148-55.
34. Ness RB, Roberts JM. Epidemiology of hypertension. In: Linheimer MD, Roberts JM, Cunningham FG editors. Chesley's hypertensive disorders of pregnancy. 2 ed. Stamford: Appleton and Lange; 1999. p. 43-65.
35. Olah KS, Redrnan CWG, Gee H. Management of severe, early pre-eclampsia: is conservative management justified? Eur J Obstet Gynecol Reprod Biol 1993;51:175-80.
36. Barton JR, Witlin AG, Sibai BM. Management of mild preeclampsia. Clin Obstet Gynecol 1999;42:455-69.
37. Caetano M, Ornstein MP, von Dadelszen P, Hannah ME, Logan A, Gruslin A et al. A survey of Canadian physicians regarding the diagnosis and evaluation of hypertension in pregnancy. Hypertens Pregn 2004;23:197-210.
38. Caetano M, Ornstein MP, von Dadelszen P, Hannah ME, Logan A, Gruslin A et al. A survey of Canadian practitioners regarding the management of hypertension in pregnancy. Hypertens Pregn 2004;23:61-74.
39. Hayter MA, Anderson L, Claydon J, Magee LA, Liston RM, Lee SK et al. Variations in early and intermediate neonatal outcomes for inborn infants admitted to a Canadian NICU and born of hypertensive pregnancies. J Obstet Gynaecol Can 2005;27:25-32.
40. von Dadelszen P, Magee LA, Devarakonda RM, Hamilton T, Ainsworth LM, Yin R et al. The prediction of adverse maternal outcomes in pre-eclampsia. J Obstet Gynaecol Can 2004;26:871-9.
41. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: Simplified newborn illness severity and mortality risk scores. J Pediatr 2001;138:92-100.
42. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Grit Care Med 1996;24:743-52.
43. Knaus W, Wagner D, Draper E. APACHE III study design: analytic plan for evaluation of severity and outcome in intensive care unit patients. Implications. Crit Care Med 1989;17 12 Pt 2.:S219-21.
44. Knaus W, Wagner D. APACHE III study design: analytic plan for evaluation of severity and outcome in intensive care unit patients. Individual patient decisions. Crit Care Med 1989;17 12 Pt 2.:S204-9.
45. Knaus W, Draper E, Wagner D. APACHE III study design: analytic plan for evaluation of severity and outcome in intensive care unit patients. Introduction. Crit Care Med 1989;17 12 Pt 2.:S176-80.
46. Knaus W, Wagner D, Draper E. APACHE III study design: analytic plan for evaluation of severity and outcome in intensive care unit patients. Development of APACHE. Crit Care Med 1989;17 12 Pt 2.:S181-5.
47. Richardson D, Tarnow-Mordi WO, Lee SK. Risk adjustment for quality improvement. Pediatrics 1999;103 1 Suppl E.:255-65.
48. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. CMAJ 1999;161 Suppl 12:51-17.
49. Milholland AV, Wheeler SG, Heieck JJ. Medical assessment by a Delphi group opinion technic. N Engl J Med 1973;288:1272-5.
50. Pill J. The Delphi method: substance, context, a critique and an annotated bibliogrpahy. Socio-Economic Planning Science 1971;5:57-71.
51. Menzies J, Magee L, MacNab Y, Li L, Lam E, Stuart H et al. The effect of instituting standing orders on the incidence of adverse maternal outcomes. Hypertens Pregn 2004;23 Suppl 1:146.
52. Tuffnell DJ, Walker JJ, Mason GC, Lindow S, Lyond G, Russell I et al. Regional guidelines for the management of severe pre-eclampsia. Leeds: Yorkshire Obstetric Critical Care Group; 2002.
53. Martin JN Jr, May WL, Magann EF, Terrone DA, Rinehart BK, Blake PG. Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. Am J Obstet Gynecol 1999;1806 Pt 1.:1407-14.
54. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:1877-90.
55. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995;345:1455-63.
56. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327:955-60.
57. Magee LA, Miremadi S, Li J, Cheng C, Ensom MHH, Carleton B et al. Does concomitant therapy of nifedipine with magnesium sulfate increase the risk of neuromuscular blockade? Am J Obstet Gynecol 2005;193:153-63.
58. Lenfant C, Chobanian AV, Jones DW, Roccella EJ, Joint National Committee on the Prevention DEaToHBP. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JNC 7.: resetting the hypertension sails. Hypertension 2003;41:1179.
59. Whitworth JA, World Health Organization ISoHWG. 2003 World Health Organization WHO./International Society of Hypertension ISH. statement on management of hypertension. J Hypertens 2003;21:1983-92.
60. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. British Hypertension Society guidelines for hypertension management 2004 BHS-IV.: summary. BMJ 2004;328:634-40.
61. Misra DP. The effect of the pregnancy-induced hypertension on fetal growth: a review of the literature. Paediatr Perinat Epidemiol 1996;10:244-63.
62. Ferrazzani S, Caruso A, De Carolis S, Martino IV, Mancuso S. Proteinuria and outcome of 444 pregnancies complicated by hypertension. Am J Obstet Gynecol 1990;162:366-71.
63. Mabie WC, Pernoll ML, Biswas MK. Chronic hypertension in pregnancy. Obstet Gynecol 1986;67:197-205.
64. Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 1994;171:410-6.
65. Barton JR, O'Brien JM, Bergauer NK, Jacques DL, Sibai BM. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol 2001;184:979-83.
66. Brown MA, Buddle ML. The importance of nonproteinuric hypertension in pregnancy. Hypertens Pregn 2002;14:57-65.
67. Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol 1998;105:1177-84.
68. Sibai BM, Abdella TN, Anderson GD. Pregnancy outcome in 211 patients with mild chronic hypertension. Obstet Gynecol 1983;61:571-6.
69. Sibai BM, Anderson GD. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet Gynecol 1986;67:517-22.
70. Sibai BM, Lindheimer MD, Hauth J, Caritis S, VanDorsten P, Klebanoff M et al. for the National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes. N Engl J Med 1998;339:667-71.
71. Lapillonne A, Peretti N, Ho PS, Claris O, Salle BL. Aetiology, morphology and body composition of infants born small for gestational age. Acta Paediatr Suppl 1997;423:173-6.
72. Barker DJ. The long-term outcome of retarded fetal growth. Clin Obstet Gynecol 1997;40:853-63.
73. Eriksson JG, Forsen T, Tuomilehto J, Winter PD, Osmond C, Barker DJ. Catch-up growth in childhood and death from coronary heart disease: longitudinal study. BMJ 1999;318:427-31.
74. Forsen T, Eriksson JG, Tuomilehto J, Osmond C, Barker DJ. Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study. BMJ 1999;319:1403-7.
75. Osmond C, Barker DJ, Winter PD, Fall CH, Simmonds SJ. Early growth and death from cardiovascular disease in women. BMJ 1993;307:1519-24.
76. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2000;4.:CD002863.
77. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000;355:87-92.
78. von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can 2002;24:941-5.
79. Bortolus R, Ricci E, Chatenoud L, Parazzini F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. BJOG 2000;107:792-4.
80. Catalano D, Ercolano S, Pollio F, Ascione L, Russo C, DeSanti B et al. [Evaluation of nifedipine monotherapy in the management of pregnancy hypertension]. G Ital Ostet Ginecol 1997;6:373-5. Italian.
81. Elhassan EM, Mirghani OA, Habour AB, Adam I. Methyldopa versus no drug treatment in the management of mild pre-eclampsia. East Afr Med J 2002;79:172-5.
82. Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br J Obstet Gynaecol 1998;105:718-2.
83. Odendaal HJ, Schabort I, Pattinson RC. Prazosin for the treatment of hypertension in pregnancy: a randomized control trial. Oxford Database of Perinatal Trials 1991; Version 1.2 Disk Issue 6.
84. Blake S, MacDonald D. The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment. Br J Obstet Gynaecol 1991;98:244-8.
85. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2001;2.:CD002252.
86. Borghi C, Immordino V, Esposti D, Boschi S, Cassani A, Bentivenga C et al. Comparison between nifedipine-GITS and methyldopa on blood pressure control, utero-placental hemodynamic and fetal outcome in patients with pre-eclampsia. Hypertens Pregn 2000;19 Suppl:P8.
87. Casavilla F, Ruda Vega H. Prospective and randomized study of mepindolol and alpha-methyldopa efficacy in arterial hypertension AH treatment during pregnancy. Proceedings of the World Congress of Gynecology and Obstetrics, 1988, October 23-25, Rio de Janeiro, Brazil.
88. Duggan PM, McCowan LM, Stewart AW. Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension. Aust N Z J Obstet Gynaecol 1992;32:335-8.
89. Faneite PJ, Gonzalez X, Salazar G. [Evaluation of antihypertensives in pregnancy: Prospective randomized study of mepindolol and alpha methyldopa]. Revista de Obstetricia y Ginecologia de Venezuela 1988;139-143. Spanish.
90. Hall DR, Odendaal HJ, Steyn DW, Smith M. Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: a randomised controlled trial. BJOG 2000;107:759-65.
91. Kahhale S, Alves EA, Takiuti NH, Zugaib M. Efficacy and safety of isradipina and atenolol in hypertensive disorders in pregnancy. Hypertens Pregn 2004;19:98.
92. Laivuori HM, Laakso M, Tikkanen MJ, Cacciatore B, Ylikorkala RO, Kaaja RJ. Short-term metabolic effects of isradipine and metoprolol in pre- eclampsia. J Hypertens 1999;17:1189-94.
93. Loquet P, Renier M, Buytaert P. The influence of atenolol and pindolol on umbilical artery pulsatility index in non-proteinuric hypertension in pregnancy. Proceedings of the 6th International Congress, ISSHP, 1988, May 22-26, Montreal, Canada, 111. 1988.
94. Magee LA. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf 2001;24 6.:457-474.
95. Montan S, Ingemarsson I, Marsal K, Sjoberg NO. Randomised controlled trial of atenolol and pindolol in human pregnancy: effects on fetal haemodynamics. BMJ 1992;304 6832.:946-949.
96. Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam S. Randomised controlled trial of methyldopa and isradipine in preeclampsia-effects on uteroplacental and fetal hemodynamics. J Perinat Med 1996;24 2.:177-184.
97. Neri I, Valensise H, Facchinetti F, Menghini S, Romanini C, Volpe A. 24-hour ambulatory blood pressure monitoring: a comparison between transdermal glyceryl-trinitrate and oral nifedipine. Hypertens Pregn 1999;18:107-113.
98. Rudnicki M, Frolich A, Rasmussen WF, McNair P. The effect of magnesium on maternal blood pressure in pregnancy-induced hypertension. A randomized double-blind placebo-controlled trial. Acta Obstet Gynecol Scand 1991;70:445-50.
99. Rudnicki M, Frolich A, Pilsgaard K, Nyrnberg L, Moller M, Sanchez M et al. Comparison of magnesium and methyldopa for the control of blood pressure in pregnancies complicated with hypertension. Gynecol Obstet Invest 2000;49 4:231-5.
100. Tuimala RJ, Hartikainen-Sorri AL. Treatment of hypertension during pregnancy by beta blocking agents. Proceedings of the 4th World Congress of the ISSHP, 1984, June 18-21, Amsterdam, The Netherlands, 52. 1984.
101. Hertig AT. Vascular pathology in the hypertensive albuminuric toxemais of pregnancy. Clinics 1945;4:614.
102. Bulmer JN. Immune aspects of pathology of the placental bed contributing to pregnancy pathology. Baillieres Clin Obstet Gynaecol 1992;6:461-8.
103. Labarrere CA. Acute atherosis. A histopathological hallmark of immune aggression? Placenta 1988;9:95-108.
104. Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours post partum. Am J Obstet Gynecol 1996;174:975-82.
105. Bertoni E, Salvadori M. [Unusual infections in transplantation]. G Ital Nefrol 2002;19:560-570. Italian.
106. Borchers AT, Perez R, Kaysen G, Ansari AA, Gershwin ME. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol 1999;7:75-82.
107. Subramanian AK, Quinn TC, Kickler TS, Kasper EK, Tucker PC. Correlation of chlamydia pneumoniae infection and severity of accelerated graft arteriosclerosis after cardiac transplantation. Transplantation 2002;73:761-4.
108. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transpl Infect Dis 2001;3 Suppl 2:44-48.
109. Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ 2000;163:49-56.
110. Leinonen M, Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2002;2:11-7.
111. Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosclerosis - what we know and what we don't. Clin Microbiol Infect 2002;8:2-13.
112. von Dadelszen P, Magee LA. Could an infectious trigger explain the differential maternal response to the shared placental pathology of preeclampsia and normotensive intrauterine growth restriction? Acta Obstet Gynecol Scand 2002;81:642-8.
113. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000;181 Suppl 3:S402-S410.
114. Spina V, Aleandri V, Pacchiarotti A, Salvi M. [Immune tolerance in pregnancy. Maternal-fetal interactions]. Minerva Ginecol 1998;50:533-7.
115. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993;14:353-6.
116. Heine RP, Ness RB, Roberts JM. Seroprevalence of antibodies to Chlamydia pneumoniae in women with preeclampsia. Obstet Gynecol 2003;101:221-6.
117. Agatsuma Y, Fitzpatrick P, Lele A, Kaul A, Ogra PL. Cell-mediated immunity to cytomegalovirus in pregnant women. Am J Reprod Immunol 1981;11:174-9.
118. Rousseau T, Douvier S, Reynaud I, Laurent N, Bour JB, Durand C et al. Severe fetal cytomegalic inclusion disease after documented maternal reactivation of cytomegalovirus infection during pregnancy. Prenat Diagn 2000;20:333-6.
119. Witters I, Van RM, Fryns JP. Cytomegalovirus reactivation in pregnancy and subsequent isolated bilateral hearing loss in the infant. Genet Couns 2000;11.:375-8.
120. von Dadelszen P, Magee LA, Krajden M, Alasaly K, Popovska V, Devarakonda RM et al. Levels of antibodies against cytomegalovirus and Chlamydophila pneumoniae are increased in early onset pre-eclampsia. BJOG 2003;110:725-30.